Immunome Inc.
IMNM evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $3.05B
What it means
What to watch
Prepared research question
What matters most for IMNM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMNM
Immunome Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, with a pipeline that includes varegacestat (a gamma secretase inhibitor in Phase 3) and multiple antibody-drug conjugates (ADCs) using a proprietary TOP1 inhibitor payload.
Key risk: No revenue, net loss
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$3.05B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 8 clinical trials for Immunome Inc..
Immunome Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, with a pipeline that includes varegacestat (a gamma secretase inhibitor in Phase 3) and multiple antibody-drug conjugates (ADCs) using a proprietary TOP1 inhibitor payload.
- Cash & equivalents of $217.7M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net income of -$73.1M as of 2026-06-30 [sec].
- Shareholders' equity of $525.1M as of 2026-06-30 [sec].
- Positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat announced in December 2025 [sec_mda · as of 2026-08-11].
- Pipeline includes four clinical assets and two preclinical assets as of 2026-08-11 [sec_mda · as of 2026-08-11].
What works
- Positive topline results from the Phase 3 RINGSIDE trial of varegacestat, supporting a planned NDA filing in Q2 2026 [sec · filed 2026-04-24].
- Proprietary TOP1 inhibitor payload (HC74) used across multiple ADC programs, providing a differentiated technology platform [sec_mda · as of 2026-08-11].
- Cash position of $217.7M as of 2026-06-30 provides a runway of at least 12 months from March 2026 [sec_mda · as of 2026-05-12].
What to weigh
- No revenue generated as of 2026-06-30, with a net loss of $73.1M [sec].
- Company expects to need additional financing to support continuing operations and commercialization of varegacestat, if approved [sec_mda · as of 2026-05-12].
- Expenses expected to increase substantially as the company advances clinical development and prepares for potential commercialization [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Positive Phase 3 results for varegacestat
“In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat”
SEC MD&A · August 11, 2026
Planned NDA filing in Q2 2026
“Successful execution of the Phase 3 RINGSIDE trial and completion of critical manufacturing and non-clinical pharmacology activities position us to support our planned NDA filing in the second quarter of 2026.”
SEC filings · April 24, 2026
Cash runway of at least 12 months
“We expect that our existing cash and cash equivalents as of March 31, 2026 will be sufficient to fund our current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q.”
SEC MD&A · May 12, 2026
Proprietary TOP1 inhibitor payload
“HC74, our differentiated, novel topoisomerase 1, or TOP1, inhibitor payload, supports this strategy”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2021-09-01 · Phase3_Start: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors — Pivotal Phase 3 trial for varegacestat; positive topline results announced December 2025.
- 2025-02-26 · Phase1_Start: A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies — First ADC candidate to enter clinical trials; uses proprietary TOP1 inhibitor payload.
- 2025-03-07 · Phase1_Start: A Phase 1, Open-Label, Single- — Additional Phase 1 trial initiation; details truncated in source.
Risks & what to watch (3)›
Key risks
- No revenue, net loss — Company reported $0.0M revenue and -$73.1M net income as of 2026-06-30 [sec].
- Need for additional financing — Company states it will need additional financing to support operations and commercialization of varegacestat if approved [sec_mda · as of 2026-05-12].
- Increasing expenses — Expenses expected to increase substantially as clinical development and potential commercialization activities ramp up [sec_mda · as of 2026-08-11].
What to watch
- NDA filing for varegacestat planned for Q2 2026 [sec · filed 2026-04-24].
- Phase 1 trial of IM-1021 initiated in February 2025 [catalyst].
- Phase 1 trial of IM-3050 dosed first participant in July 2026 [sec_mda · as of 2026-08-11].
- Anticipated IND submissions for IM-1340 and IM-1335 in 2026 [sec_mda · as of 2026-08-11].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Immunome Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immunome Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.08 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 20 sells (180d)
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 17.0%
- Days to cover
- 12.4
- Shares short
- 18,604,286
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMNM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immunome Inc.?
Immunome Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, with a pipeline that includes varegacestat (a gamma secretase inhibitor in Phase 3) and multiple antibody-drug conjugates (ADCs) using a proprietary TOP1 inhibitor payload.
Who is the CEO of Immunome Inc.?
Dr. Clay B. Siegall Ph.D. is the chief executive officer of Immunome Inc. (IMNM).
Where is Immunome Inc. headquartered?
Immunome Inc. (IMNM) is headquartered in Bothell, WA, United States.
What therapeutic areas does Immunome Inc. focus on?
Immunome Inc. develops therapies across Oncology, Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.